Dengue virus type 2 (DENV-2) is one of four antigenically distinct serotypes of dengue virus, an enveloped, positive-sense RNA virus of the genus Flavivirus that causes dengue fever and severe dengue. It is transmitted primarily by Aedes mosquitoes.
Genome and Virology
DENV-2 has a single-stranded positive-sense RNA genome about 10.7 kilobases in length. A single open reading frame encodes a polyprotein that is co- and post-translationally cleaved into three structural proteins—capsid, prM/M and envelope—and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The envelope glycoprotein binds to host cell receptors such as DC-SIGN and heparan sulfate, and receptor-mediated endocytosis delivers the virion to acidic endosomes where fusion releases the genome. Replication takes place on rearranged endoplasmic reticulum membranes; NS3 acts as a helicase and protease, while NS5 functions as the RNA-dependent RNA polymerase and methyltransferase synthesising negative-strand intermediates and new genomes. DENV-2 infects dendritic cells, monocytes and endothelial cells in humans as well as midgut and salivary gland cells in Aedes mosquitoes. Several genotypes—including Asian I, Asian II, Cosmopolitan and American—display different geographic distributions and virulence. Secondary infection with DENV-2 is frequently associated with severe dengue through antibody-dependent enhancement.
Global Distribution and Severe Disease
DENV-2 circulates widely across tropical and subtropical regions of Asia, Africa and the Americas. It has caused major epidemics, such as the 1981 outbreak of dengue hemorrhagic fever in Cuba and repeated outbreaks in Southeast Asia and Latin America. Infection ranges from inapparent to classic dengue fever characterised by fever, severe headache, myalgia, retro-orbital pain and rash. Secondary infection with a different serotype can lead to severe dengue with plasma leakage, hemorrhage and shock, and DENV-2 is often implicated in these cases. The virus is sustained in an urban transmission cycle between humans and Aedes aegypti mosquitoes with seasonal peaks linked to rainfall and temperature. Prevention relies on vector control, elimination of breeding sites and vaccines like Dengvaxia, which provide variable protection among serotypes. Surveillance and genetic characterisation are important because viral diversity influences pathogenicity and vaccine performance. Dengue virus type 2 remains a major cause of morbidity in tropical regions and is notable for its association with severe disease. Understanding its replication and global spread helps to inform vaccine development and integrated vector control strategies. Related Terms: Dengue Virus 1, Dengue Virus 3, Dengue Virus 4, Flavivirus, Aedes aegypti